CASE SERIES

Secukinumab in pityriasis rubra pilaris: A case series demonstrating variable response and the need for minimal clinical datasets

Tevi Wain, MBBS, Bonita Choy, MBBS, Andrew C. Satchell, MBBS, FACD, Jane A. Woods, MBBS, FACD, and John W. Frew, MBBS, FACD

Sydney, Australia

Key words: interleukin-17A; minimal clinical dataset; pathogenesis; pathophysiology; pityriasis rubra pilaris; secukinumab; taxonomy.

INTRODUCTION

Pityriasis rubra pilaris (PRP) is a heterogeneous group of rare papulosquamous disorders characterized by folliculocentric keratinization. PRP has a bimodal incidence with equal gender predilection. It can be spontaneous in nature and associated with familial inheritance or as a paraneoplastic phenomenon. PRP has a variable clinical presentation with Griffiths criteria classifying PRP into 5 subtypes based on age of onset, clinical course, and prognosis. HIV-related PRP and paraneoplastic PRP have been proposed as additional subtypes. The pathophysiology of PRP remains unclear but is proposed to be triggered by a variety of as-yet-unidentified triggers of chronic inflammation. Reported effective treatment with etanercept, adalimumab, ustekinumab, and secukinumab implicate tumor necrosis factor α, interleukin (IL)-12/IL-23, and IL-17 as involved in the downstream inflammatory cascade, although the variability in response indicates some degree of disease heterogeneity within Griffiths subtypes. Feldmeyer et al demonstrated upregulation of helper T cell 17 cytokines including IL-17A, IL-17F, and IL-22 in lesional skin of a patient with PRP who demonstrated a rapid resolution of disease with ustekinumab. Ustekinumab has also been reported as particularly beneficial in patients with CARD14 polymorphisms.

We present a case series of 3 patients with clinical and histologic diagnoses of PRP treated with subcutaneous secukinumab per the dosing regimen for chronic plaque psoriasis (300 mg weekly on weeks 0, 1, 2, 3, and 4 and 300 mg every 4 weeks thereafter). All 3 patients had disparate clinical responses highlighting the need for further translational investigation into the pathophysiologic heterogeneity of the disease and consideration of revision of Griffiths subtyping of PRP to align with pathophysiology and treatment response rather than age of onset and extent of disease.

CLINICAL INFORMATION

Patient A, a 52-year-old man, presented with a 4-week history of rostro-caudal progression of erythema associated with palmoplantar keratoderma and nail changes. His history was relevant for type 1 diabetes mellitus controlled with insulin glargine and he denied any family history of PRP or psoriasis. He had no previous systemic treatment for his condition. Histopathology testing found vertical and horizontal...
alternating orthokeratosis and parakeratosis consistent with PRP (Fig 1). Full-body computed tomography scan and blood work did not find any suggestions of occult neoplasia. His PRP was classified as Griffiths type 1.

Patient B, a 71-year-old man, presented with a 4-year history of erythroderma, including scalp involvement and palmar keratoderma associated with a concurrent diagnosis of chronic lymphocytic leukemia (CLL) under the care of a hematologist. His condition was recalcitrant to methotrexate, acitretin, cyclosporine, fumarates, narrow-band ultraviolet B therapy, and oral steroids. His CLL was stable for the last 3 months treated with ibrutinib. Multiple biopsy

Fig 1. Histopathology of patients included in this case series. Patient A (A and B), patient B (C and D), and patient C (E and F). A, Hyperkeratosis with moderate irregular acanthosis and a moderate perivascular inflammatory infiltrate in the papillary dermis. B, Alternating orthokeratosis and parakeratosis with thickened suprapapillary plates. C, Irregular acanthosis with acantholysis. D, Orthokeratosis and parakeratosis. E, Compact orthokeratosis with focal parakeratosis. F, Some focal acantholysis is evident with perivascular lymphocytic infiltrate. (A-F, Hematoxylin eosin stain; Original magnifications: A, ×40; B, ×200; C, ×20; D, ×40; E, ×100; F, ×100.)
specimens were taken with findings of epidermal spongiosis, mild acanthosis, and superbasilar and intraepithelial acantholysis (Fig 1). Review of biopsies found previously unappreciated vertical and horizontal alternating orthokeratosis and parakeratosis (Fig 1) consistent with PRP. His PRP was classified as Griffiths type 1 (paraneoplastic).

Patient C, a 61-year-old man, presented with a 30-year history of localized plaques of erythema with folliculocentric plugging and scale to the arms, legs, and buttocks. His condition was resistant to topical steroids, oral methotrexate, ultraviolet B therapy, and acitretin. Multiple skin scrapings and tissue cultures were negative for fungi. Histopathology found orthokeratosis and parakeratosis with intraepidermal acantholysis (Fig 1). Periodic acid–Schiff staining of biopsied tissue failed to identify evidence of fungal infection. Considering the lack of response to conventional treatments, the histopathology slides were reviewed and suggested subtle signs of a diagnosis of PRP. Full-body computed tomography scan and blood work did not find occult neoplasia. His PRP was classified as Griffiths type 2.

Further clinical details are presented in Table I and Fig 2. Histopathologic slides are presented in Fig 1. All patients were treated after completing full clinical workup for biologic treatment per current guidelines14 and undergoing an age-appropriate malignancy screen based on clinical history and examination. Patient B underwent consultation with his treating hematologist to ensure that no interference with current treatment for his CLL was anticipated. All patients were treated for a total of 6 months, at which point, if complete clinical response was achieved, the drug was withdrawn to assess rates of recurrence. Blood tests were undertaken every 2 weeks until week 8, with monthly blood tests thereafter. No expected adverse events (upper respiratory tract symptoms, injection site reactions) were seen across the 5 patients. Clinical improvement was seen in patient A by week 4 of therapy with clearing in a rostro-caudal progression. At the time of publication, patient A has had no recurrence of symptoms 3 months after cessation of secukinumab. Patient B had a partial response, and his CLL remained stable throughout the 6 months of therapy. Patient C had a paradoxical worsening during the first 8 weeks of therapy leading to temporary treatment withdrawal for 4 weeks. Resumption of treatment at patient request did not lead to further worsening of disease and resulted in partial improvement over the next 12 weeks (Table I).

### DISCUSSION

This case series combined with previous case reports suggest that secukinumab can be a rapid and effective option for complete clearance of type 1/2 PRP. In the setting of complete rapid clinical response to secukinumab in type 1 PRP, withdrawal of the drug after complete disease control does not result in recurrence of symptoms. This finding leads to the suggestion that the role of biologic therapy in type 1 PRP is to fast-track the resolution of the inflammatory cascade potentiated by the unknown (but presumably singular) trigger event. The lack of complete response in cases, including those associated with positive family history of PRP or paraneoplastic cases, suggests that an underlying recurrent inflammatory trigger remains present. It is yet unknown if a proportion of PRP patients do not respond to IL-17 antagonists, and if this is indicative of alternate inflammatory pathways being involved in the pathogenesis of disease. Publication bias in the reporting of dramatic responses of PRP to biologic therapy makes assessment of these cases problematic outside of a large multicentre cohort study. The stability in the status of CLL in patient B also suggests that in this case, treatment with secukinumab and concomitant ibrutinib does not result in any untoward adverse events or progression of pre-existing CLL.

Further translational efforts are required to consistently assess baseline levels of inflammatory cytokines in PRP patients treated with biologic therapies. A proposed minimum clinical dataset15 (Table II) would also begin to standardize reports of biologic therapy in PRP to guide further immunopathogenic

### Table I. Demographic and clinical details pertaining to the case reports of patients A, B, and C at baseline (week 0) and up to week 24 of treatment

| Demographics | IGA | DLQI | % BSA |
|--------------|-----|------|-------|
| Patient | Age, y | Gender | Griffiths subtype | Wk 0 | Wk 4 | Wk 12 | Wk24 | Wk 0 | Wk 4 | Wk 12 | Wk24 | Wk 0 | Wk 4 | Wk 12 | Wk 24 | Wk 0 | Wk 4 | Wk 12 | Wk 24 |
| A | 52 | M | 1 | 9 | 3 | 1 | 0 | 24 | 21 | 12 | 7 | 90 | 54 | 28 | 0 |
| B | 71 | M | 1 | 9 | 7 | 7 | 7 | 28 | 27 | 28 | 26 | 85 | 85 | 80 | 80 |
| C | 61 | M | 2 | 4 | 6 | WH | 4 | 20 | 28 | WH | 16 | 36 | 45 | WH | 25 |

BSA, Body surface area; DLQI, dermatology life quality index; IGA, investigator global assessment; WH, withheld.
Fig 2. Variability in response to secukinumab for clinically and histologically diagnosed PRP. A, Patient A week 0. B, Patient A week 24. C, Patient B week 0. D, Patient B week 8. E, Patient C week 0. F, Patient C week 8. Patient B had paraneoplastic PRP secondary to CLL and had only limited response to secukinumab over a 6-month period. Patient A had rapid and complete response with no evidence of disease recurrence up to 6 months after cessation of secukinumab. Patient C had paradoxical worsening of disease and ceased treatment at week 8.
Table II. Proposed minimal clinical dataset for the treatment of PRP using biologic agents including all reported cases of treatment with secukinumab (including the 3 reported cases)

| Case | Reference | Patient age at onset | Patient gender | Time since disease onset | Griffiths subtype of PRP | Medical comorbidities | FHx Pso | FHx PRP | Treatment history | Prior treatment | Prior response | AE | Percentage of body surface area improvement | Baseline quality of life assessment | Clinical endpoints |
|------|-----------|---------------------|----------------|-------------------------|-------------------------|-----------------------|---------|---------|-------------------|----------------|--------------|----|--------------------------------------------|-----------------------------|------------------|
| 1    | Kevric et al | 54 | F | 52 y | V | NR | NR | NR | NR | MTX | Limited | Limited | Limited | Limited | Limited | Limited | Limited | Limited | Limited | Limited | Limited | Limited | Limited | Limited | Limited | Limited | Oral & esophageal candidiasis |
| 2    | Gauci et al | 33 | F | 9 y | II | Vesicoureteral reflux, hydronephrosis | No | No | No | Acitretin | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Oral & esophageal candidiasis |
| 3    | Schuster et al | 67 | M | Acute | I | NR | No | No | No | Acitretin | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Oral & esophageal candidiasis |
| 4    | Mariasy et al | 68 | M | Several wk | I | NR | NR | NR | NR | Acitretin | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Oral & esophageal candidiasis |
| 5    | Patient A | 52 | M | 4 wk | I | T1DM | No | No | No | Nil | NA | NA | NA | 24/30 | 100 | NR | 14 wk | Nil |
| 6    | Patient B | 71 | M | 4 y (Paraneoplastic) | I | CLL | No | No | No | Acitretin | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Minimal | Oral & esophageal candidiasis |
| 7    | Patient C | 61 | M | 30 y | Nil | Yes | No | No | No | MTX | 20/30 | 11 | NR | NA | Worsening |

*AE, Adverse events; FHx, family history; MTX, methotrexate; NA, not applicable; NBUB, narrowband ultraviolet B; NR, not reported; pso, psoriasis; T1DM, type 1 diabetes mellitus.*
stratification of disease and eventual revision of Griffiths’ taxonomy. This would also hopefully lead to more targeted therapy and predictable clinical outcomes for patients suffering with PRP.

The authors thank Dr Kerry Crotty, Kossard Dermatopathology, Sydney, Australia; Dr Christopher Henderson, Department of Anatomical Pathology, South Western Sydney Area Health Service, Sydney Australia; and Dr Leonard Wu, Dorevitch Pathology, Melbourne Australia.

REFERENCES

1. Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol. 1980; 5(1):105-112.
2. Bar-ilan E, Gat A, Sprecher E, Zeeli T. Paraneoplastic pityriasis rubra pilaris: case report and literature review. Clin Exp Dermatol. 2017;42(1):54-57.
3. Bell SL, Patel AN, Leach IH, Cohen SN. Consider triggers for pityriasis rubra pilaris. Clin Exp Dermatol. 2014;39:403-405.
4. Garcovich S, Di Giampetruzzi AR, Antonelli G, Garcovich A, Didona B. Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series. J Eur Acad Dermatol Venereol. 2010;24(8):881-884.
5. Adnot-Desanlis L, Antonicelli F, Tabary T, Bernard P, Reguiazi Z. Effectiveness of infliximab in pityriasis rubra pilaris is associated with pro-inflammatory cytokine inhibition. Dermatology. 2013;226:41-46.
6. Petrof G, Almaani N, Archer CB, Griffiths WA, Smith CH. A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists. J Eur Acad Dermatol Venereol. 2013;27(1):131-135.
7. Napolitano M, Lembo L, Fania L, Abeni D, Didona D, Didona B. Ustekinumab treatment of pityriasis rubra pilaris: a report of five cases. J Dermatol. 2018;45(2):202-206.
8. Kevric I. Response of persistent juvenile pityriasis rubra pilaris to secukinumab. J Am Acad Dermatol. 2016;74(5):AB268.
9. Gauci ML, Jachiet M, Gottlieb J, et al. Successful treatment of type II pityriasis rubra pilaris with secukinumab. JAAD Case Rep. 2016;2(6):462-464.
10. Schuster D, Pfister-Wartha A, Bruckner-Tuderman L, Schempp CM. Successful Treatment of Refractory Pityriasis Rubra Pilaris With Secukinumab. JAMA Dermatol. 2016;152(11):1278-1279.
11. Mariasy, Campanelli, Sauder DN. Remission of Pityriasis Rubra Pilaris with IL-17A Antagonist Secukinumab. Austin J Dermatolog. 2016;3(5):1063.
12. Feldmeyer L, Mylonas A, Demaria O, et al. Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris. JAMA Dermatol. 2017;153(4):304-308.
13. Eytan O, Sarig O, Sprecher E, van Steensel MA. Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14. Br J Dermatol. 2014;171(2):420-422.
14. Smith CH, Anstey AV, Barker JNWN, et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161(5):987-1019.
15. Svensson-Ranallo PA, Adam TJ, Sainfort F. A framework and standardized methodology for developing minimum clinical datasets. AMIA Jt Summits Transl Sci Proc. 2011;2011:54-58.